The final outcomes from a Providence Cancer Institute-sponsored phase Ib trial were published in npj Breast Cancer on June 21. The trial evaluated pembrolizumab, an immunotherapy, with either weekly paclitaxel or flat-dose capecitabine in treating patients with metastatic triple-negative breast cancer. Both regimens achieved predetermined safety and efficacy outcomes. The study, “A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer,” was led by David B. Page, M.D., Providence Cancer Institute. npj Breast Cancer is an open access, multidisciplinary research journal dedicated to publishing leading-edge breast cancer research and treatment.